GLPwatch

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

NCT05230615 · Completed

Last updated 2026-05-28

This study is testing how an oral medication called semaglutide affects people with type 2 diabetes in Italy as part of their regular medical care.

Status Completed The study has finished.
Type Observational
Participants 458 people
Who can join Ages 18+ · all sexes
Timeline Started 2022-04 · est. completion 2023-10
Where 2 sites · Italy

What this study is testing ClinicalTrials.gov NCT05230615 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.

Treatments tested

Main thing measuredChange in HbA1c (Glycated haemoglobin)
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05230615 ↗